- In a Special Meeting, Merrimack Pharmaceuticals (NASDAQ:MACK +0.7%) stockholders voted to approve the sale of ONIVYDE and generic DOXIL to Ipsen for up to ~$1B.
- The deal will give Merrimack the resources to fund the development of three new compounds targeting cancer while boosting Ipsen's portfolio, which has traditionally focused on endocrinology.
- Previously: Ipsen to acquire oncology assets from Merrimack (Jan. 9)
Merrimack shareholders back asset sale to Ipsen, deal to close shortly
Recommended For You
About MACK Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
MACK | - | - |
Merrimack Pharmaceuticals, Inc. |